Sofinnova Partners Appoints Mary McCarthy as Partner for the Firm’s Industrial Biotech Strategy
20.4.2023 11:00:00 EEST | Business Wire | Press release
Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Mary McCarthy as Partner at Sofinnova Partners, joining the growing Sofinnova Industrial Biotech Strategy team. She will use her extensive experience and network to help identify the most promising early-stage companies developing biotech-enabled sustainable solutions in agriculture, food, chemicals, and materials. The Sofinnova Industrial Biotech Strategy has made 24 investments to date and is actively investing out of its third fund of €175M.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420005098/en/
Mary McCarthy (Photo: Business Wire)
Before joining Sofinnova Partners, Mary was a Partner at Brightlands Venture Partners (BVP) where she was the Fund Manager of the BVP Renewable Chemistry Fund and served on various boards. With over 24 years in chemistry and materials, Mary has occupied various roles in the sector: She was CEO of a start-up developing materials for the circular economy and worked at SABIC for 15 years, where she held various functions in R&D, HR, Change Management, and Corporate Venturing.
Michael Krel, Partner at Sofinnova Partners, said: "Mary is a perfect addition to our team with broad experience in the venture, start-up and corporate world. This appointment is another step forward in the growth of our industrial biotech strategy; it bolsters our commitment to identifying and supporting early-stage companies that have the potential to develop innovations with strong environmental impact."
Joško Bobanović, Partner at Sofinnova Partners, said: "Mary joins our team at an exciting time of growth and evolution of the industrial biotech ecosystem. With her track record of successful investments, Mary will strengthen our capacity to meet the increasing demand for innovative and sustainable solutions for the environment."
Mary McCarthy, Partner at Sofinnova Partners, said: "I'm very pleased to join Sofinnova Partners. The Industrial Biotech team is a recognized pioneer in the sector with a wealth of accumulated knowledge. I am looking forward to contributing to the team’s mission of finding deeptech solutions with strong environmental impact that can truly change the world for the better."
Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, said: "Mary’s appointment strengthens Sofinnova’s leadership position in industrial biotech and reinforces the work this team has been doing for over a decade in forging a strong platform through investments in sustainability. Industrial biotech is a crucial pillar for the future of our firm, and Mary’s extensive network, ability to recognize disruptive technology, and genuine commitment to make the global economy more sustainable will undoubtedly contribute to accelerating this trajectory."
Mary holds a PhD in chemistry from University College Dublin, Ireland and held postdoctoral fellowships at the University of Amsterdam, the Netherlands and the Max Planck Institute für Kohlenforschung, Germany.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005098/en/
Contact information
Bommy Lee
Head of Communications
Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
United Kingdom
Optimum Strategic Communications
Hollie Vile
sofinnova@optimumcomms.com
+44 (0) 20 3922 0900
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Pierluigi Cavarai
pierluigi.cavaraiext@havaspr.com
+39 (0) 392 77 999
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Telekom Srbija Group Secures Landmark International Credit Ratings from Fitch and Moody’s, Marking Historic First for Western Balkans26.2.2026 14:22:00 EET | Press release
Telekom Srbija Group today announced that it has received international credit ratings from Fitch Ratings and Moody’s Investors Service, marking a historic milestone as the first company headquartered in the Western Balkans to achieve this distinction. Fitch Ratings has affirmed Telekom Srbija’s long-term issuer rating in connection with its debut issuance of bonds on the international financial market, recognizing the Group’s strong market position, resilient cash flow profile and disciplined financial strategy. Moody’s Investors Service has assigned a B1 rating to the company’s bond issuance, underscoring Telekom Srbija’s established operating performance and strategic importance within the regional telecommunications sector. As the first Western Balkans–headquartered company to issue bonds on the international financial market and secure ratings from two of the world’s leading credit rating agencies, Telekom Srbija has set a new benchmark for the region’s corporate sector. The achie
PNCC Selects LotusFlare to Power Digital BSS and Commerce Platform for New 4G/5G Standalone Network26.2.2026 14:04:00 EET | Press release
LotusFlare, a provider of a cloud-native, AI-driven digital commerce and monetization platform for communications service providers (CSPs), today announced that Palau National Communications Corporation (PNCC) has selected it to provide a comprehensive commerce and monetization platform, including a full-stack digital business support system (dBSS) as part of PNCC’s broader 4G/5G Standalone (SA) network modernization programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226869218/en/ Palau National Communications Corporation (PNCC) The LotusFlare solution will support PNCC subscribers across mobile, fixed broadband, and digital TV services, while enabling unique multi-tenant capabilities aligned with PNCC’s long-term digital and regional strategy. PNCC has embarked on a comprehensive technology modernization program focused on increasing speed-to-market, enhancing customer experience, and long-term operational efficie
GoldState Music and Bridgepoint Announce Strategic Partnership Targeting Growth Investments26.2.2026 14:00:00 EET | Press release
Bridgepoint, one of the world’s leading mid-market investors, today announced that it has entered into a strategic partnership with GoldState Music, a premier music investment platform, committing a significant investment as lead investor in GoldState’s Growth Strategy. The capital will support a dedicated investment programme focused on building and scaling high-quality music-oriented businesses globally. GoldState Music is a private investment firm founded in 2022 by industry veteran Charles Goldstuck, who played an integral role in the development of many music enterprises as well as in the careers of numerous major artists and songwriters. The company’s Growth Strategy is focused on investing in and scaling growing businesses operating in the music value chain, combining deep industry relationships with institutional investment discipline and structured capital solutions. Under the strategic partnership announced today, GoldState will originate and actively manage the Growth Strate
Amazfit Introduces the Active 3 Premium: Turning Daily Movement into Meaningful Progress for Entry-Level Runners26.2.2026 14:00:00 EET | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Amazfit Active 3 Premium, a compact, 4-button smartwatch designed as an entry point into structured running and hybrid training. Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Its compact design makes it easy to train across environments, from neighborhood runs to studio floors, offering a capable, approachable experience without feeling overbuilt or intimidating. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226378156/en/ Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Unlike high-performance racing watches that can feel overwhelming,
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics26.2.2026 14:00:00 EET | Press release
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "We anticipate this acquisition will significantly expand our oncology pipeline with late-preclinical and Phase 1-ready assets in a multi-billion dollar market with substantial unmet medical needs. With this acquisition, if completed, we will strengthen our armamentari
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom